isoxazoles has been researched along with trametinib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kakefuda, R; Tajima, N; Tanimoto, A; Watanabe, Y; Yamaguchi, T | 1 |
| Choi, J; Jin, HR; Kim, SW; Lee, DH; Lee, MH; Nam, KY; Oh, B; Park, KS; Yang, H | 1 |
2 other study(ies) available for isoxazoles and trametinib
| Article | Year |
|---|---|
Suppressive effect of an orally active MEK1/2 inhibitor in two different animal models for rheumatoid arthritis: a comparison with leflunomide.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Collagen Type II; Cytokines; Enzyme Inhibitors; Humans; Interleukin-6; Isoxazoles; Leflunomide; Lipopolysaccharides; Lymphocyte Activation; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mice; Mice, Inbred ICR; Pyridones; Pyrimidinones; Rats; Rats, Sprague-Dawley | 2012 |
The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Resorcinols; Signal Transduction; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |